New schizophrenia drug shows promise in early trial
NCT ID NCT07288333
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called NBI-1117570 in 120 adults with schizophrenia who need hospital care. The goal is to see if it improves symptoms like hallucinations and disorganized thinking better than a placebo. Participants take the drug or a placebo daily for 35 days, and researchers measure changes using a standard symptom scale.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NBI-1117570
What this could lead to
If it works, this could point toward a new treatment option for schizophrenia that helps control symptoms during acute episodes.
What could go wrong
This is an early Phase 2a trial with only 120 participants, so results may not apply to everyone. The drug may not work better than placebo, and side effects are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Neurocrine Clinical Site
RECRUITINGKazanlak, 6100, Bulgaria
-
Neurocrine Clinical Site
RECRUITINGPazardzhik, 4400, Bulgaria
-
Neurocrine Clinical Site
RECRUITINGTargovishte, 7700, Bulgaria
-
Neurocrine Clinical Site
RECRUITINGLondon, SE5 8AZ, United Kingdom
-
Neurocrine Clinical Site
RECRUITINGOxford, OX3 7JX, United Kingdom